Knowde Enhanced TDS
Identification & Functionality
- Animal Feed & Nutrition Functions
- Ingredients
- Acetylsalicylic Acid
- Technologies
Applications & Uses
- Markets
- Dose
- Fattening pigs: 50 mg of acetylsalicylic acid/kg bw/day, equivalent to 77 mg of medicine/kg bw/day administered for 10 days
- Broilers: 50 mg/kg bw/day equivalent to 77 mg of medicine/kg bw /day administered for 5 days
- Indications
- Symptomatic treatment of fever
- Wait Time
Meat:
- Chicken: 1 day
- Pork: 1 day
Properties
- Physical Form
- Composition
- Pharmacological Properties
Pharmacodynamic Properties:
Acetylsalicylic acid is an anti-inflammatory, analgesic and antipyretic agent. Acetylsalicylic acid interferes with prostaglandin synthesis by irreversibly inhibiting cyclooxygenase or COX (in all its isoforms), through an enzyme acetylation process. COX-1 is responsible for the synthesis of prostaglandins in response to hormonal stimuli, and maintains normal renal function, gastric mucosal integrity, and hemostasis. COX-2 is inducible in many cells in response to some inflammatory mediators. There is a third isoform of COX (COX-3), which seems to be, in fact, an isoenzyme of COX-1 or even its catalytic fraction. COX-3 is especially expressed in the brain and heart, being strongly blocked by nonspecific NSAIDs (such as aspirin and paracetamol). Acetylsalicylic acid produces analgesia by acting at the central level on the hypothalamus and at the peripheral level, blocking the generation of pain impulses, by blocking the synthesis of prostaglandins mediated by the inhibition of cyclooxygenase (COX). The anti-inflammatory effect is due to the same biochemical action, which translates into a reduction in the synthesis of prostaglandins E and F, decreasing capillary permeability and the release of destructive enzymes from lysosomes: For its part, the antipyretic effect of acetylsalicylic acid It is the result of the inhibition of prostaglandin synthesis in the hypothalamus, reducing the abnormally high temperature by acting on the thermoregulatory center and producing peripheral vasoconstriction. Vasodilation increases sweating and therefore heat loss. On the other hand, prostaglandins, especially PGE1, are potent endogenous pyrogens. Various adverse reactions have been described, generally related to high doses, prolonged treatment or the existence of factors or conditions that increase drug sensitivity. The most frequent are related to the gastrointestinal tract, as a consequence of the reduction in the concentration of prostaglandins, essential for maintaining the integrity of the digestive mucosa. The observed chronic nephrotoxicity is also related to the inhibition of prostaglandin synthesis, since prostaglandins are essential in maintaining renal blood flow in most animal species. Additionally, acetylsalicylic acid develops a platelet antiaggregant action, associated with the irreversible inhibition of COX, which also participates in the synthesis of common thromboxane precursors (proaggregants) and prostacyclin, PGItwo(antiplatelet). The predominance of the antiaggregant action is due to the fact that prostacyclin is synthesized by vascular endothelial cells, capable of producing new molecules of cyclooxygenase after initial inactivation by acetylsalicylic acid. In contrast, platelets (which are cell fractions and therefore lack a nucleus) are unable to produce new molecules of cyclooxygenase, with which precursors of thromboxanes are synthesized.
Pharmacokinetic Data:
In pigs, after oral administration of acetylsalicylic acid, absorption is rapid and incomplete, estimating an absolute bioavailability of the order of 50%. Acetylsalicylic acid is detected in plasma for a very short time due to rapid hydrolysis that occurs in the gastric mucosa, liver, and plasma. Salicylic acid from aspirin deacetylation is the pharmacologically active metabolite and its plasma half-life in pigs is 6 hours. After administration of the recommended dose in drinking water, the steady state is reached in about 12 hours. Steady-state plasma concentrations range from 22 mg/L (Cssmax) and 4mg/l (Cssmin). After discontinuation of treatment, plasma concentrations of salicylic acid decrease rapidly, being of the order of 0.25 mg/l at 4 hours. Following absorption, salicylate is widely distributed in most tissues and transcellular fluids. It crosses the placental barrier. In the pig, 70% is bound to plasma proteins. The volume of distribution (Vd) is 0.2L/Kg in this species. The metabolism of salicylic acid takes place mainly in the liver. It is excreted in the urine, partly metabolized as salicyluric acid and partly as glucuronide conjugates. The fraction that is eliminated unchanged is pH dependent: elimination is faster when the urine pH is acidic. Very young animals, with immature metabolism systems, show slight changes in metabolism and excretion. Thus, in pigs less than one month old, a prolongation in the elimination half-life is observed together with differences in the proportions of glucuronide and salicylurate derivatives, reaching values similar to adults after 30 days of age, a time at which The mechanisms involved in the metabolism and excretion of salicylates have been fully developed. In chicken, after oral administration of acetylsalicylic acid, absorption is rapid and complete, estimating an absolute bioavailability of 100%. After administration of the recommended dose in drinking water, the steady state is reached in about 12 hours. Steady-state plasma concentrations range from 23 mg/L (Cssmax) and 20 mg/l (Cssmin) determining an average concentration (Cssav) of 21.50 mg/l. After discontinuation of treatment, plasma concentrations of salicylic acid decrease rapidly, being of the order of 1 mg/l at 12 hours.
| Value | Units | Test Method / Conditions | |
| Acetylsalicylic Acid | 650.0 | mg/g | — |
Packaging & Availability
- Packaging Type
- Available Packaging
- 10 X 100g Container: 100 g aluminum bag closed by heat sealing, Cardboard box with 10 aluminum bags of 100 g.
- 1 Kg container: 1 Kg aluminum bag closed by heat sealing.
- 25 Kg container: 25 Kg aluminum bag closed by heat sealing
- Nature and composition of primary packaging
- 100 g container: 100 g aluminum bag closed by heat sealing
- Cardboard box with 10 aluminum bags of 100 g
- Label – prospectus for the box, in which the batch and the manufacturing expiration date will have been previously marked
- Label – leaflet for the bag, in which the batch and the manufacturing expiration date will have been previously marked.
- 1 Kg container
- 1 Kg aluminum bag closed by heat sealing
- Label – prospectus, in which the batch and the manufacturing expiration date will have been previously marked
- 25 Kg container
- 25 Kg aluminum bag closed by heat sealing
- Label – prospectus, in which the batch and the manufacturing expiration date will have been previously marked
- Not all formats may be marketed
Storage & Handling
- Shelf Life
- Shelf life of the veterinary medicinal product as packaged for sale: 2 years
- Shelf life after dissolution or reconstitution according to instructions: 12 hours
- Storage and Handling
This veterinary medicinal product does not require any special storage conditions.
- Disposal
All unused veterinary medicinal products or the residues derived from them must be disposed of in accordance with current regulations.